Category: AbbVieSyndicate content

Baxter reveals plans to split pharma, medical products businesses

March 27, 2014 by Brad Perriello

Baxter International says it plans to go the way of rivals Abbott and Covidien in splitting its pharmaceuticals and medical products businesses into separate companies.

Baxter reveals plans to split pharma, medical products businesses

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Abbott's Q4, 2013 earnings meet The Street

January 22, 2014 by Brad Perriello

Abbott's 4th-quarter and 2013 earnings per share meet expectations on Wall Street, but another revenue miss pushes shares down today.

Abbott's Q4 earnings meet The Street, but miss for 2013

Report: Abbott pharma spinout expects layoffs

April 16, 2013 by Arezu Sarvestani

An anonymous source tells Bloomberg Businessweek that Abbott pharmaceutical spin-off AbbVie will fire its cardiology drugs salesforce amid growing competition from generics.

Layoffs illustration

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Abbott profits sink on 1-time charges in final months before the split

January 23, 2013 by MassDevice staff

Medical products giant Abbott Laboratories details its operations in the final months before spinning out its research pharmaceuticals division, with 1-time expenses dragging down its bottom line.

Abbott Laboratories logo

Medical products giant Abbott (NYSE:ABT) took a hit to its bottom line in the final quarter of 2012, with profits dropping by more than ⅓ as the company prepared for an overhaul.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Post-split Abbott announces FDA win for Xience Xpedition stent

January 3, 2013 by MassDevice staff

Healthcare giant Abbott starts off its post-split season with an FDA win for its Xience Xpedition drug-eluting stent system.

Abbott logo

Abbott (NYSE:ABT) announced FDA approval for its Xience Xpedition coronary stent, planning commercial launch in the U.S. immediately.

Abbott's Xience line of drug-eluting stents are the only such devices on the U.S. market approved for "direct stenting," in which the stent is delivered to the targeted blood vessel without a prior procedure preparing the lesion.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Abbott prepares to split | MassDevice.com On Call

December 31, 2012 by MassDevice staff

Healthcare giant Abbott will split into 2 parts starting tomorrow, separating its proprietary drug division from the generics, diagnostics, devices and nutrition arm.

MassDevice On Call

MASSDEVICE ON CALL — Healthcare giant Abbott (NYSE:ABT) will officially split into 2 parts starting tomorrow, essentially separating the proprietary drug division from the rest of the company.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp